Biolevate Raises €6 Million in Seed Round
Biolevate, a Paris, France-based health-tech startup that aims to use AI to transform medical writing processes, has raised €6 million in seed funding.
The round was led by EQT Ventures, with participation from bpifrance.
EQT Ventures is a venture capital firm based in Stockholm, Sweden, that invests in seed-stage, early-stage, and later-stage companies. Founded in 2015, the firm focuses on the information technology and SaaS sectors across Europe and the United States.
The company plans to use the funding to enhance its platform and expand its team, aiming to improve healthcare efficiency and innovation.
Founded in 2023, Biolevate is developing an AI-assisted medical writing platform designed to streamline the creation of regulatory-compliant documents for the healthcare and pharmaceutical industries. The platform, ELISE, utilizes advanced AI technologies like NLP, Computer Vision, and Graph Neural Networks to assist in document creation, reduce manual work, and accelerate the time-to-market for new medical products.
Funding Details
Company: Biolevate SAS
Raised: €6.0M
Round: Seed Round
Funding Date: November 2024
Lead Investor: EQT Ventures
Additional Investor: bpifrance
Company Website: https://www.biolevate.com/
Software Category: AI Medical Writing